1. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost- effectiveness modelling study 
Dr Jennifer Uyei, PhD, David A Fiellin, MD, Marianne Buchelli, MPH, Ramon Rodriguez-Santana, MPH, Prof R Scott Braithwaite, MD 
The Lancet Public Health 
Volume 2, Issue 3, Pages e133-e140 (March 2017)
DOI: /S (17)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

2. Figure 1 Lifetime survival probability by strategy
PrEP=pre-exposure prophylaxis.
The Lancet Public Health 2017 2, e133-e140DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

3. Figure 2
Scenarios when naloxone distribution plus linkage to addiction treatment is no longer cost saving compared with naloxone distribution alone
Corresponding rates are in parentheses.
The Lancet Public Health 2017 2, e133-e140DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

4. Figure 3
Scenarios when ICERs for the combination of naloxone distribution, PrEP, and linkage to addiction treatment were more than US$100 000
Corresponding rates are in parentheses. ICER=incremental cost-effectiveness ratio. PrEP=pre-exposure prophylaxis.
The Lancet Public Health 2017 2, e133-e140DOI: ( /S (17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions